Sores

CMS Confirms CPT Code 64590 for eCoin® Tibial Neurostimulator

Retrieved on: 
Wednesday, December 14, 2022
American Medical Association, CMS, Indian Medical Association, Vasculitis, Food and Drug Administration, Leg, Magnet, Food, Centers for Medicare & Medicaid Services, Edema, Nursing care plan, MRI, Pregnancy, Letter, Patient, New Technology Management, Ambulatory Payment Classification, Sores, Hospital, APC, Division, FDA, CPT, Urinary incontinence, EMI, US Foods, Trauma, PMA, Safety, Physician, Burns, AMA, Government, ASC, Infection, Diathermy, Medicare, Foot, Medical device, Pharmaceutical industry, Medical imaging

The eCoinsystem is a leadless tibial neurostimulator for the treatment of urgency urinary incontinence (UUI).

Key Points: 
  • The eCoinsystem is a leadless tibial neurostimulator for the treatment of urgency urinary incontinence (UUI).
  • CPT code 64590 is assigned to Ambulatory Payment Classification (APC) 5464.
  • The eCoin device is a coin-sized neurostimulator which is implanted subcutaneously in the lower leg during a minimally invasive, outpatient procedure utilizing local anesthetic.
  • About The eCoinSystemThe eCoin Peripheral Neurostimulator ("eCoin") is part of the eCoin Peripheral Neurostimulator System ("eCoin System") including device accessories.

CANADA'S TOP FAST FOOD BRANDS FAILING ON CHICKEN WELFARE: REPORT

Retrieved on: 
Tuesday, December 13, 2022
Pizza Hut, Heart, Starbucks, Perch, Chicken, Limp, Make in India, Macdonald, Chronic pain, Science, Heart failure, Tier 1, Animal, Performance, Sores, Meat, Muscle weakness, BCC, Policy, McDonald's, World Animal Protection, KFC, Pressure, Burger King, Food industry, Good, Selective breeding, Pecking order, Poultry, Fast food, Dominoes

The report highlights the failures among the biggest fast-food brands in Canada for not acting to address important animal welfare issues in their supply chain for chickens raised for meat.

Key Points: 
  • The report highlights the failures among the biggest fast-food brands in Canada for not acting to address important animal welfare issues in their supply chain for chickens raised for meat.
  • "We're urging these companies to take public concerns on animal welfare seriously and sign on to the Better Chicken Commitment."
  • The Better Chicken Commitment requires that companies:
    Use chicken breeds that grow at a healthier rate.
  • World Animal Protection has commissioned The Pecking Order every year since 2019 to monitor the progress of major fast-food brands.

The PotShop, a Leading Weed-Producing Platform in California, Announces Newly Added Products

Retrieved on: 
Wednesday, November 23, 2022
Farm, Collection, THC, Sores, Genetics, Migraine, Symptoms of COVID-19, CBD, Medicinal plants, Drug

San Francisco, California--(Newsfile Corp. - November 23, 2022) - The PotShop, http://www.thepotshop.cc, has established itself as a marijuana company located in California, USA. The company has expanded new services in the latest development by increasing its vast collection of new cannabis products. The products are readily available from 20th November 2022, worldwide where marijuana is legal, such as in California.

Key Points: 
  • Recently, the company added new products to its vast collection of cannabis products in California.
  • San Francisco, California--(Newsfile Corp. - November 23, 2022) - The PotShop, http://www.thepotshop.cc , has established itself as a marijuana company located in California, USA.
  • The company has expanded new services in the latest development by increasing its vast collection of new cannabis products.
  • The products are readily available from 20th November 2022, worldwide where marijuana is legal, such as in California.

Inflammatory Bowel Disease Treatment Global Markets Report 2022: Focus on Aminosalicylates, Corticosteroids, TNF Inhibitors, IL Inhibitors, Anti-integrin, JAK Inhibitors - Forecasts to 2026 & 2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022
Biotechnology, Pharmaceutical, Health, IL, Prevalence, Inflammatory bowel disease, JAK, AI, Bowel obstruction, Ulcerative colitis, Ferring Pharmaceuticals, Inflammatory Bowel Diseases, Sores, Macrophage, Inflammation, Human body, Therapy, Artificial intelligence, Pharmacy, Organization, Crohn's disease, TNF, IBD, APG system, Ulcer, Pharmaceutical industry

The inflammatory bowel disease treatment market consists of sales of inflammatory bowel disease therapeutics and drugs by entities (organizations, partnerships, and sole proprietors) that are used to provide medical treatment for inflammatory bowel diseases.

Key Points: 
  • The inflammatory bowel disease treatment market consists of sales of inflammatory bowel disease therapeutics and drugs by entities (organizations, partnerships, and sole proprietors) that are used to provide medical treatment for inflammatory bowel diseases.
  • The main drug class of inflammatory bowel disease treatment include aminosalicylates, corticosteroids, TNF inhibitors, IL inhibitors, anti-integrin, JAK inhibitors, and others.
  • Both orally and injectable administered inflammatory bowel disease treatment are used in the treatment of Crohn's disease and ulcerative colitis.
  • The rising prevalence of Crohn's disease and ulcerative colitis is significantly driving the inflammatory bowel disease treatment market.

FDA Approves Medicines360's LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Eight Years

Retrieved on: 
Monday, November 14, 2022
SAN, Polyethylene, Internal bleeding, Endometritis, Body mass index, ACCESS, IUS, Pain, Infertility, Levonorgestrel, IUD, Population, PID, Woman, Obstetrics, Faecal calprotectin, Infection, Uterus, American Journal of Obstetrics and Gynecology, Abdominal pain, Risk, Safety, Sores, FDA, Pregnancy, Gynaecology, Ectopic pregnancy, Medicine, Fibroid, Department, HIV, Time, Barium sulfate, Birth certificate, University of Pennsylvania Health System, Vaginal bleeding, Multimedia, American Journal, Pelvic inflammatory disease, Hysterectomy, Death, Patient, Chills, Pelvic pain, Policy, Condom, CEO, BMI, Sex, STD, Allergy, Professor, AbbVie, Review, Perforation, Fever, Food, Shanda, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Birth control, Dietary supplement, Pharmaceutical industry

SAN FRANCISCO, Nov. 14, 2022 /PRNewswire/ -- Medicines360, a global nonprofit organization with a mission to expand women's access to quality medicines, announced today that the U.S. Food and Drug Administration (FDA) has approved Medicines360's Supplemental New Drug Application (sNDA) to extend the duration of use of Liletta® (levonorgestrel-releasing intrauterine system) 52 mg to prevent pregnancy for up to eight years. This approval is based on data from ACCESS IUS (A Comprehensive Contraceptive Efficacy & Safety Study of an IUS) that Medicines360 first published in the American Journal of Obstetrics and Gynecology in May 2022. With this FDA approval, LILETTA has one of the longest approved durations of use for a hormonal intrauterine device (IUD or IUS) in the U.S.

Key Points: 
  • LILETTA was approximately 99% effective in preventing pregnancy for up to eight years in a diverse population of women.
  • LILETTA is a hormone-releasing system placed in the uterus to prevent pregnancy for up to eight years.
  • LILETTA (levonorgestrel-releasing intrauterine system) 52mg is a hormone-releasing system placed in your uterus to prevent pregnancy for as long as you want for up to 8 years.
  • If you get pregnant while using LILETTA, you may have an ectopic pregnancy, which means the pregnancy is not in the uterus.

Fenway Health Provides Blueprint for More Effective Federal Response to Monkeypox

Retrieved on: 
Tuesday, September 13, 2022
Health policy, World, Therapy, Fenway Health, Sex, COVID-19, Policy, Epidemic, FDA, Food, Defense Production Act of 1950, Social stigma, Research, Association, World Health Organization, Vaccination, HIV, Health communication, Contract, Face, COVID, Patient, Defense, MPP, Senate, Technology, Vaccine, Public health, Solution, Sores, Doctor of Philosophy, Smallpox, BBC, Monkeypox, Congress, Man, Skin, Food and Drug Administration, NIH, Education, Color, Disease, Death, Pharmaceutical industry

BOSTON, Sept. 13, 2022 /PRNewswire-PRWeb/ -- As U.S. monkeypox diagnoses top 21,000 amid the federal government's failure to contain the initial outbreak of the virus in May, Fenway Health has released a policy brief that offers solutions to a range of problems that have exacerbated the spread of the virus.

Key Points: 
  • "We have stockpiles of medications to treat monkeypox, effective vaccines to protect us from the virus, and effective testing.
  • The U.S. has failed to contain monkeypox by failing to effectively mobilize existing public health infrastructure to aid communities affected by the virus.
  • Due to poor health communication, many providers and patients are unaware that treatment for monkeypox is available.
  • Finally, Congress must appropriate funding for the monkeypox response and for research to better contain and eliminate the virus.

St. Luke's Infectious Disease Experts Call on Dentists to be Alert for Monkeypox

Retrieved on: 
Monday, August 15, 2022
Sores, Monkeypox, Herpes simplex, Multimedia, Medicine, University Health Network, Public health, Dentist, Palate, Fluid mechanics, Aphthous stomatitis, COVID, Myalgia, COVID 19, Throat, Trauma, Infection, Pachydactylus labialis, Mouth, Rash, American Dental Association, Man, Fever, Patient, COVID-19, Oral and maxillofacial surgery, Partner (business rank), Skin, Google, Network, DMD, Dental hygienist, Tongue, Disease, Vaccine, Dentistry, St Luke's

"Early recognition by all healthcare providers including dentists can potentially bring the spread of this disease to a halt."

Key Points: 
  • "Early recognition by all healthcare providers including dentists can potentially bring the spread of this disease to a halt."
  • Dr. Jahre said St. Luke's is calling on the dental community to be alert for monkeypox because Network doctors have begun seeing oral monkeypox symptoms.
  • Monkeypox is transmitted most commonly through direct contact with body fluids or lesions of the body of someone who has the disease.
  • Currently more than 95% of the monkeypox cases involve men who have sexual relations with men who have multiple sexual partners.

Empathy for Itch 2022 Launches with 'Pet Check' List for Pet Owners

Retrieved on: 
Thursday, August 11, 2022
Sores, The, Cat, Veterinarian, CAVD, Face, Diagnosis, Dog, Mars, Incorporated, Parasitism, Trauma, Royal Canin, Itchy, Animal nutritionist, Pain, PETS, Dandruff, Quality of life, Hair loss, Greasy, Mars, Tick, Skin, Ice, Hair, Empathy, By, Abuse, Red, Allergy, Vaccine, Veterinary medicine, Petroleum jelly, Medical imaging, Sphinx

"Checking your pet for any changes related to their skin is easy to do, by making regular skin checks part of your pet's daily routine."

Key Points: 
  • "Checking your pet for any changes related to their skin is easy to do, by making regular skin checks part of your pet's daily routine."
  • Doing at home checks is critical for preventative care, as it allows pet owners to actively understand what their pet is experiencing.
  • When it comes to pet skin health issues, there's no better team than a pet owner and their veterinary team.
  • For more information on the Empathy for Itch Campaign, management tips or tools to help your first vet visit be successful, visit our website at www.cavd.ca/empathy-for-itch .

Navamedic ASA - Exclusive agreement with Vectans Pharma for the unique cold sore treatment product Sitavig®

Retrieved on: 
Thursday, August 4, 2022
Sores, Pachydactylus labialis, CEO, Population, Lip, Sale, Herpes labialis, Mouth, Marketing, Patient, Aciclovir, Nordic, Acquisition, Partnership, OTC, Herpes simplex virus, Ownership, Pharmaceutical industry, Vaccine

This entitles Navamedic to the ownership of the marketing authorizations for the product in these regions.

Key Points: 
  • This entitles Navamedic to the ownership of the marketing authorizations for the product in these regions.
  • It is a key element of our value creation strategy to secure and increase value creation through ownership of products and exclusive marketing rights," says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.
  • Cold sores - also called fever blisters - is a common and recurring condition that affects about 20 - 40% of the population.
  • Sitavig (acyclovir) is a 50mg Muco-Adhesive Buccal tablet that represents a breakthrough in the treatment of cold sores.

Jazz Pharmaceuticals Presents Positive Data from Phase 2/3 Trial of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma at the ASCO 2022 Annual Meeting

Retrieved on: 
Tuesday, June 7, 2022
Fatigue, American Cancer Society, Leukemia, Toxicity, National Cancer Institute, LBL, Adult, Death, Pediatric Blood & Cancer, Escherichia coli, Pain, Blood, Childhood leukemia, Multimedia, Pseudomonas fluorescens, Allergy, Acute leukemia, Cancer, Leg, Non-Hodgkin lymphoma, Infection, Headache, Food, RTOR, DOI, Pain scale, Bleeding, Acute lymphoblastic leukemia, Fever, Jazz Pharmaceuticals, PDQ, Population, Bone marrow, Regulation of tobacco by the U.S. Food and Drug Administration, ALL, Cancer research, Nausea, Tongue, Hypersensitivity, Tightness, Lymphoma, Trae Crowder, Patient, Fast Track, Throat, Sores, Liver, Nursing, Appetite, FDA, Twitter, Birth, Arm, Safety, Physical Sciences-Oncology Centers, Pancreas, Pharmaceutical industry, Birth control, Vaccine, Dietary supplement, Oil, Hematology

DUBLIN, June 7, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from a Phase 2/3 trial, developed and conducted in close collaboration with the Children's Oncology Group (COG), evaluating the intramuscular (IM) administration of Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn) in adult and pediatric patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) who have developed hypersensitivity to an E. coli-derived asparaginase. These results will be presented as an oral presentation today at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting.

Key Points: 
  • Females of reproductive potential should use effective contraception (other than oral contraceptives) during treatment and for 3 months following the final dose.
  • Do not breastfeed while receiving RYLAZE and for 1 week after the final dose.
  • Tell your healthcare provider if there are any side effects that are bothersome or that do not go away.
  • We have a diverse portfolio of marketed medicines and novel product candidates, from early-to late-stage development, in neuroscience and oncology.